Gebasaxturev is under clinical development by Merck and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gebasaxturev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cavatak (Coxsackievirus A21, CVA-21) is under development for the treatment of colorectal cancer, metastatic uveal melanoma, solid tumors, non-muscle invasive bladder cancer, metastatic castrate-resistant prostate cancer, head and neck cancer, triple-negative breast cancer, advanced or metastatic head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, hepatocellular carcinoma, metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer, chronic lymphocytic leukemia, acute myeloid leukemia, prostate cancer, pancreatic cancer, metastatic melanoma and bladder cancer. It was also under development for the treatment of glioma, mesothelemia, breast cancer, and multiple myeloma. Coxsackievirus A21 is administered through intratumoral, intravesical and intravenous route. Cavatak is the formulation of the Coxsackievirus Type A21 (CVA21). Coxsackievirus A21 acts via ICAM-1 targeted virotherapy which delays or avoids the impact of virus neutralization. The drug candidate is developed using oncolytic virotherapy technology.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Gebasaxturev’s drug-specific PTSR and LoA scores, buy the report here.